Clinical Trial Update: Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a combination of anti-VEGF and anti-angiopoietin-2 for diabetic macular edema has completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• Anti-vascular Endothelial Growth Factor plus Anti-angiopoietin 2 in Fixed combination therapy

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Diabetic Macular Edema | Phase 2 | Status: COMPLETED | Results posted: 2018-10-03